Search Results - "Tan, Wan Ling"

Novel therapeutic targets on the horizon for lung cancer by Tan, Wan-Ling, MRCP, Jain, Amit, MMed, Takano, Angela, MD, Newell, Evan W, PhD, Iyer, N Gopalakrishna, MD, Lim, Wan-Teck, MRCP, Tan, Eng-Huat, MMed, Zhai, Weiwei, PhD, Hillmer, Axel M, PhD, Tam, Wai-Leong, PhD, Tan, Daniel S W, Dr

“…Summary Lung cancer is a leading cause of cancer-related mortality worldwide, and is classically divided into two major histological subtypes: non-small-cell…”
Get full text

From presentation to paper: Gender disparities in oncological research by Dijksterhuis, Willemieke P.M., Stroes, Charlotte I., Tan, Wan‐Ling, Ithimakin, Suthinee, Calles, Antonio, Oijen, Martijn G.H., Verhoeven, Rob H.A., Barriuso, Jorge, Oosting, Sjoukje F., Ivankovic, Daniela Kolarevic, Furness, Andrew J.S., Bozovic‐Spasojevic, Ivana, Gomez‐Roca, Carlos, Laarhoven, Hanneke W.M.

“…Gender disparities in scientific publications have been identified in oncological research. Oral research presentations at major conferences enhance visibility…”
Get full text

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases by Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel S W, Lim, Darren Wan-Teck

“…Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced…”
Get full text

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma by Lim, Darren Wan-Teck, Kao, Hsiang-Fong, Suteja, Lisda, Li, Constance H., Quah, Hong Sheng, Tan, Daniel Shao-Weng, Tan, Sze-Huey, Tan, Eng-Huat, Tan, Wan-Ling, Lee, Justina Nadia, Wee, Felicia Yu-Ting, Jain, Amit, Goh, Boon-Cher, Chua, Melvin L. K., Liao, Bin-Chi, Ng, Quan Sing, Hong, Ruey-Long, Ang, Mei-Kim, Yeong, Joe Poh-Sheng, Iyer, N. Gopalakrishna

“…Single-agent checkpoint inhibitor (CPI) activity in Epstein-Barr Virus (EBV) related nasopharyngeal carcinoma (NPC) is limited. Dual CPI shows increased…”
Get full text

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases by Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel S W, Lim, Darren Wan-Teck

Get full text

Comparison of hepatocellular carcinoma in Eastern versus Western populations by Choo, Su Pin, Tan, Wan Ling, Goh, Brian K. P., Tai, Wai Meng, Zhu, Andrew X.

“…Hepatocellular carcinoma (HCC) is a heterogeneous disease that remains highly prevalent in many Asian countries and is the second most common cause of…”
Get full text

Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer by Lai, Gillianne G Y, Lim, Tse Hui, Lim, John, Liew, Perry J R, Kwang, Xue Lin, Nahar, Rahul, Aung, Zaw Win, Takano, Angela, Lee, Yin Yeng, Lau, Dawn P X, Tan, Gek San, Tan, Sze Huey, Tan, Wan Ling, Ang, Mei-Kim, Toh, Chee Keong, Tan, Bien Soo, Devanand, Anantham, Too, Chow Wei, Gogna, Apoorva, Ong, Boon Hean, Koh, Tina P T, Kanesvaran, Ravindran, Ng, Quan Sing, Jain, Amit, Rajasekaran, Tanujaa, Yuan, Ju, Lim, Tony Kiat Hon, Lim, Alvin S T, Hillmer, Axel M, Lim, Wan Teck, Iyer, N Gopalakrishna, Tam, Wai Leong, Zhai, Weiwei, Tan, Eng-Huat, Tan, Daniel S W

“…Mesenchymal epithelial transition factor ( MET) activation has been implicated as an oncogenic driver in epidermal growth factor receptor ( EGFR)-mutant…”
Get full text

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis by Tan, Aaron C., Lai, Gillianne G.Y., Tan, Gek San, Poon, Shou Yu, Doble, Brett, Lim, Tse Hui, Aung, Zaw Win, Takano, Angela, Tan, Wan Ling, Ang, Mei-Kim, Tan, Bien Soo, Devanand, Anantham, Too, Chow Wei, Gogna, Apoorva, Ong, Boon-Hean, Koh, Tina P.T., Kanesvaran, Ravindran, Ng, Quan Sing, Jain, Amit, Rajasekaran, Tanujaa, Lim, Alvin S.T., Lim, Wan Teck, Toh, Chee Keong, Tan, Eng-Huat, Lim, Tony Kiat Hon, Tan, Daniel S.W.

“…•Upfront NGS is feasible and cost-effective in an EGFR mutant predominant population.•Characterizing the wider genomic profile may yield important…”
Get full text

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients by Sutiman, Natalia, Tan, Shao Weng, Tan, Eng Huat, Lim, Wan Teck, Kanesvaran, Ravindran, Ng, Quan Sing, Jain, Amit, Ang, Mei Kim, Tan, Wan Ling, Toh, Chee Keong, Chowbay, Balram

“…Activating mutations in the EGFR gene have been shown to confer sensitivity to EGFR tyrosine kinase inhibitors in patients with advanced NSCLC. However, wide…”
Get more information

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC by Tan, Wan Ling, Chua, Kevin L M, Lin, Chia-Chi, Lee, Victor H F, Tho, Lye Mun, Chan, Anthony W, Ho, Gwo Fuang, Reungwetwattana, Thanyanan, Yang, James C, Kim, Dong-Wan, Soo, Ross A, Ahn, Yong Chan, Onishi, Hiroshi, Ahn, Myung-Ju, Mok, Tony S K, Tan, Daniel S W, Yang, Fan

“…Stage III NSCLC represents a heterogeneous disease for which optimal treatment continues to pose a clinical challenge. Recent changes in the American Joint…”
Get more information

Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC by Saw, Stephanie P.L., Low, Yi Fen, Lai, Gillianne G.Y., Chan, Landon L., Wong, Wesley K.Y., Tsui, Giselle, Chen, Olivia H., Seet, Amanda O.L., Tan, Wei Chong, Tan, Aaron C., Chan, Johan W.K., Teh, Yi Lin, Tan, Wan-Ling, Ng, Quan Sing, Ang, Mei-Kim, Kanesvaran, Ravindran, Lim, Darren W.T., Tan, Daniel S.W., Mok, Tony S.K., Li, Molly S.C.

“…•Addition of pemetrexed-platinum on first-line osimertinib progression is effective.•Patients with L858R and baseline CNS metastases also benefit from this…”
Get full text

Advances in systemic treatment for nasopharyngeal carcinoma by Tan, Wan-Ling, Tan, Eng-Huat, Lim, Darren Wan-Teck, Ng, Quan-Sing, Tan, Daniel Shao-Weng, Jain, Amit, Ang, Mei-Kim

“…Nasopharyngeal carcinoma (NPC) is a unique disease endemic in Asia. It is etiologically linked to the Epstein-Barr virus and is both radio- and…”
Get full text

Multispectral raster-scanning optoacoustic mesoscopy differentiate lesional from non-lesional atopic dermatitis skin using structural and functional imaging markers by Li, Xiuting, Moothanchery, Mohesh, Kwa, Cheng Yi, Tan, Wan Ling, Yew, Yik Weng, Thng, Steven Tien Guan, Dinish, U.S., Attia, Amalina Binte Ebrahim, Olivo, Malini

“…Atopic dermatitis (AD) is a chronic and pruritic skin inflammatory disease causing a significant burden to health care management and patient’s quality of…”
Get full text

Healthcare policy for COVID‐19 patients on haemodialysis: Adapting to the changing needs of the Omicron variant by Koh, Deanna Xiuting, Chen, James Jianhong, Lee, Martin Yong Kwong, Tan, Chieh Suai, Tan, Elizabeth Wan Ling, Chong, Si Jack, Dan, Yock Young

Get full text

Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure by Saw, Stephanie P L, Tan, Gek San, Tan, Wei Chong, Tan, Aaron C, Lai, Gillianne G Y, Lim, Darren W T, Kanesvaran, Ravindran, Tan, Wan Ling, Tan, Sze Huey, Lim, Kiat Hon, Skanderup, Anders J, Tan, Daniel S W

“…To compare the performance of droplet digital polymerase chain reaction (ddPCR) and plasma next-generation sequencing (NGS) in detecting clearance of plasma…”
Get full text

Abstract 5114: Ultra-sensitive detection of minimal residual disease (MRD) through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer (NSCLC) by Tan, Aaron C., Saw, Stephanie P., Lai, Gillianne G., Chua, Kevin L., Takano, Angela, Ong, Boon-Hean, Koh, Tina P., Jain, Amit, Tan, Wan Ling, Ng, Quan Sing, Kanesvaran, Ravindran, Rajasekaran, Tanujaa, Deochand, Sunil, Maloney, Dillon, Afterman, Danielle, Lauterman, Tomer, Friedman, Noah, Bourzgui, Imane, Ramaraj, Nidhi, Donenhirsh, Zohar, Veksler, Ronel, Rosenfeld, Jonathan, Kandasamy, Ravi, Tavassoly, Iman, Oklander, Boris, Zviran, Asaf, Lim, Wan-Teck, Tan, Eng-Huat, Skanderup, Anders J., Ang, Mei-Kim, Tan, Daniel S.

“…Abstract Background: Early detection of recurrence and monitoring of MRD post-surgery is critical for clinical decision-making to tailor adjuvant therapy. In…”
Get full text

Is There a Unicorn Among the Uncommon EGFR Mutations? by Tan, Wan Ling, Lim, Darren Wan-Teck

Get more information

Real world outcomes of patients with non-clear cell renal cell carcinoma: A single Asian centre experience by Chan, Johan W.K., Peh, Daniel, Tan, Wei Chong, Tan, Hui Shan, Ng, Quan Sing, Rajasekaran, Tanujaa, Teh, Yi Lin, Saw, Stephanie, Tan, Wan Ling, Lai, Gillianne, Jain, Amit, Kanesvaran, Ravindran

“…632 Background: Non-clear cell RCC (nccRCC) represents a heterogenous group of tumors which is less well studied than clear cell RCC. Clinical data supporting…”
Get full text

Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC by Saw, Stephanie Pei Li, Low, Yi Fen, Lai, Gillianne, Chan, Landon, Wong, Wesley K. Y., Tsui, Giselle, Chen, Olivia, Seet, Amanda Oon Lim, Tan, Wei Chong, Tan, Aaron C., Chan, Johan W.K., Teh, Yi Lin, Tan, Wan Ling, Ng, Quan Sing, Ang, Mei-Kim, Kanesvaran, Ravindran, Lim, Darren Wan-Teck, Tan, Daniel Shao-Weng, Mok, Tony S. K., Li, Molly SC

“…e20531 Background: First-line pemetrexed-platinum chemotherapy + osimertinib (Pem-Plat-Osi) improves progression free survival as compared to osimertinib (Osi)…”
Get full text

Elucidating the genomic and transcriptomic landscape of L858R vs ex19del EGFR-mutated NSCLC by Saw, Stephanie Pei Li, Pang, Mengyuan, Yeo, Jia Chi, Alvarez, Jacob, Sim, Ngak Leng, Ng, Win Pin, Lai, Gillianne, Tan, Aaron C., Jain, Amit, Tan, Wan Ling, Kanesvaran, Ravindran, Ng, Quan Sing, Lim, Darren Wan-Teck, Ang, Mei-Kim, Lim, Tony Kiat Hon, Ong, Boon-Hean, Chua, Kevin Lee Min, Tan, Daniel Shao-Weng, Skanderup, Anders

“…8530 Background: Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is heterogeneous and L858R derive less benefit from…”
Get full text